Stock Analysis
Roivant Sciences Ltd. Common SharesROIV
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy19 analystsPrice is 66% of the way from the year's low to its high.
Cash covers 3586% of debt · Q1 2027.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Financial Health75
Risks
- Valuation20
- Growth0
Weak fundamentals at a demanding price.
Bull Case
- ✓Altman Z 38.7 — safe-zone balance sheet
What's happening with ROIV
Profile
Strong financial health; growth, profitability, moat, valuation and earnings quality lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-3.1%)0/25
- P/S (2932.2x)0/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (-37.8%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-85.2%)0/25
- ROE (-6.1%)0/25
- Net margin (-3629.2%)0/25
- Operating margin (-15499.9%)0/25
- Financial Health75/100 · Strong
- Altman Z (38.74)25/25
- Current ratio (16.72)25/25
- Interest coverage (-9.0x)0/25
- Net cash / debt (Net cash)25/25
- Quality30/100 · Weak
- Piotroski F (2/9)5/25
- Beneish M (-3.04)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 7945.5%)0/25
- Moat0/100 · Weak
- ROIC >12% years (n/a)0/25
- Median gross margin (n/a)0/25
- FCF-positive years (0/5 yrs)0/25
- Worst-year net margin (worst -3629.2%)0/25
Risk Flags
- ⚠Negative FCF margin (-2.0%) — burning cash
- ⚠SBC 4190.9% of revenue — real dilution cost
- ⚠5 loss-making years in recent history
- ⚠Interest coverage -9.0× — thin debt cushion
- ⚠Revenue shrinking 37.8%/yr
About Roivant Sciences Ltd. Common Shares
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Show more
It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Headquarters: LONDON · Employees: 721 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-3.1%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -34.2%–-2.5% · 93rd pct
P/S (TTM)2932.20xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 36.7x–3656.2x · 93rd pct
EV/EBITDA5.3xA
Grade A: CheapEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales3098.7xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio4.92xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-85.2%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-6.1%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-5.0%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-3629.2%D
Grade D: LowNet Income / Revenue
Operating Margin-15499.9%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin-8159.0%D
Grade D: LowGross Profit / Revenue
FCF Margin-200.0%D
Grade D: LowFCF / Revenue
True FCF Margin-13374.4%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR-37.8%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+3.8%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue4190.9%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score38.74A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio16.72xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio16.72xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-9.0xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT2.9xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.02xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt35.86xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
30DPiotroski F-Score2/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score-3.04A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability7945.5%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue99.4%D
Grade D: HeavyTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.00xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Epperly Melissa B, Filed | Epperly Melissa B, | Option exercise | -17750 | |
Epperly Melissa B, Filed | Epperly Melissa B, | SellOpen market sale | -900 | |
Epperly Melissa B, Filed | Epperly Melissa B, | SellOpen market sale | -16850 | |
Epperly Melissa B, Filed | Epperly Melissa B, | Option exercise | +17.8K | |
Sukhatme Mayukh Filed | Sukhatme Mayukh | Tax withholding | -46879 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Venker Eric Filed | Venker Eric | Option exercise | -200000 | |
Venker Eric Filed | Venker Eric | SellOpen market sale | -200000 | |
Venker Eric Filed | Venker Eric | Option exercise | +200.0K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/5 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-3629.2%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$5.32
Cash & short-term investments per share (Finnhub)
Book Value / Share$5.86
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$107.15M
Total debt obligations (short + long term)
Cash & Equiv.$3.84B
Cash and short-term investments
Net Debt$-3.73BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$4.92B
Shareholders' equity (book value)
Asset / Liability13.80xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$24.22B
Current Market Capitalization
Beta1.20B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Roivant Sciences Ltd. Common Shares (ROIV)
ROIV is down 1.50% at the last close. Roivant Sciences Ltd. Common Shares meets only 2 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 38.74 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -3.04 suggests a low likelihood of earnings manipulation. Revenue has been contracting (CAGR ≈ -38%), which weighs on the growth outlook.
- Free-cash-flow margin is negative (-200%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -9.0× leaves little room for earnings shocks.
- Roivant Sciences Ltd. Common Shares posted a net loss in 5 of 5 available completed fiscal years (2022–2026).
- At a valuation score of 20/100, ROIV trades at a premium to its historical multiples.
See how ROIV ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ROIV moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 9 | Regular | 35.44 | +3.60% | 2.63 |
| Oct 9 | After-hours | 35.44 | +3.60% | 2.63 |
Frequently Asked Questions about ROIV
What is the current Roivant Sciences Ltd. Common Shares (ROIV) stock price?
ROIV is trading at $33.53 at the last market close, down 1.50% on the session. PreMarketPrice tracks ROIV pre-market, intraday and after-hours prices.
Is ROIV stock a buy right now?
PreMarketPrice's quantitative model rates Roivant Sciences Ltd. Common Shares's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ROIV stock overvalued?
Roivant Sciences Ltd. Common Shares trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Roivant Sciences Ltd. Common Shares report earnings?
No confirmed earnings date is currently scheduled for ROIV. The Earnings section lists recent reports and updates as dates are announced.
What sector does Roivant Sciences Ltd. Common Shares operate in?
Roivant Sciences Ltd. Common Shares operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Roivant Sciences Ltd. Common Shares do?
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
About Roivant Sciences Ltd. Common Shares (ROIV) Stock
Roivant Sciences Ltd. Common Shares (ROIV) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Roivant Sciences Ltd. Common Shares is trading at $33.53, down 1.50% on the day with a market capitalization of $24.2 billion. The financial health score for ROIV is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ROIV stock.
ROIV Stock Analysis & Key Metrics
On PreMarketPrice, you can track Roivant Sciences Ltd. Common Shares (ROIV) across multiple dimensions:
- Pre-market price & movement: Real-time ROIV stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ROIV with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Roivant Sciences Ltd. Common Shares across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ROIV.
- Sector peers: Compare ROIV against 6 other healthcare stocks on key financial metrics.
Is ROIV a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Roivant Sciences Ltd. Common Shares (ROIV) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Roivant Sciences Ltd. Common Shares (ROIV) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.